Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12340741 | 0.78 | SMN1; SMN2 (0.36) | PYCR1ALDH1A1MAPK1MAPT | |
| SCHEMBL10168080 | 0.76 | PYCR1 (0.42) | PYCR1ALDH1A1MAPK1MEN1KMT2A | |
| SCHEMBL12340510 | 0.76 | PYCR1 (0.42) | PYCR1 | |
| SCHEMBL29958026 | 0.76 | PYCR1 (0.42) | PYCR1 | |
| SCHEMBL12164465 | 0.74 | PYCR1 (0.49) | PYCR1ALDH1A1MAPK1CA1CA2 | |
| SCHEMBL307129 | 0.74 | PYCR1 (0.49) | PYCR1ALDH1A1MAPK1CA1CA2 | |
| SCHEMBL29676673 | 0.74 | PYCR1 (0.49) | PYCR1ALDH1A1MAPK1CA1CA2 | |
| SCHEMBL30169578 | 0.74 | PYCR1 (0.49) | PYCR1ALDH1A1MAPK1CA1CA2 | |
| SCHEMBL29951023 | 0.73 | PGK1 (0.38) | ALDH1A1 | |
| SCHEMBL12630661 | 0.73 | APLNR (0.41) | ALDH1A1CA1CA2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268835-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-7622605-B2 | Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same | PFIZER INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20090281122-A1 | Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase, and Compositions and Treatments Using the Same | PFIZER INC | 2009-11-12 | — | — | US | disclosed |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | AGOURON PHARMACEUTICALS, INC. | 2007-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281122-A1 | Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase, and Compositions and Treatments Using the Same | RNASE1, GTF3C4, POLRMT | PYCR1 1998/4885ALDH1A1 792/4885MAPK1 3744/4885 |
| US-20070015764-A1 | INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME | RNASE1, GTF3C4, POLRMT | PYCR1 1998/4885ALDH1A1 792/4885MAPK1 3744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.